JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 93 filers reported holding JOUNCE THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $50 | -100.0% | 44,849 | -53.9% | 0.01% | -80.0% |
| Q3 2022 | $228,000 | -68.3% | 97,317 | +0.4% | 0.03% | -58.9% |
| Q3 2021 | $720,000 | +101.1% | 96,900 | +84.1% | 0.07% | +82.5% |
| Q2 2021 | $358,000 | +66.5% | 52,623 | +71.4% | 0.04% | +14.3% |
| Q4 2020 | $215,000 | -6.1% | 30,696 | -36.3% | 0.04% | -38.6% |
| Q1 2020 | $229,000 | +63.6% | 48,169 | +14.9% | 0.06% | +200.0% |
| Q3 2019 | $140,000 | +129.5% | 41,912 | +241.1% | 0.02% | +171.4% |
| Q2 2019 | $61,000 | -74.5% | 12,287 | -68.2% | 0.01% | -70.8% |
| Q1 2019 | $239,000 | -46.3% | 38,602 | -70.8% | 0.02% | -52.9% |
| Q4 2018 | $445,000 | -34.3% | 132,100 | +26.9% | 0.05% | +37.8% |
| Q3 2018 | $677,000 | – | 104,100 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $22,527,000 | 93.16% |
| TRV GP III, LLC | 1,148,780 | $9,592,000 | 2.40% |
| Deep Track Capital, LP | 4,000,000 | $33,400,000 | 2.36% |
| Ally Bridge Group (NY) LLC | 575,000 | $4,801,000 | 1.68% |
| Logos Global Management LP | 1,350,000 | $11,273,000 | 1.16% |
| PFM Health Sciences, LP | 3,972,868 | $33,173,000 | 1.13% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 245,829 | $2,053,000 | 0.83% |
| Yorktown Management & Research Co Inc | 137,300 | $1,146,000 | 0.77% |
| Sofinnova Investments, Inc. | 1,582,777 | $13,216,000 | 0.77% |
| ACUTA CAPITAL PARTNERS, LLC | 127,500 | $1,065,000 | 0.45% |